Secukinumab plus surgery for moderate to severe hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This trial tests whether combining the drug secukinumab with surgery can help people with moderate to severe hidradenitis suppurativa (HS). It looks at how well this combination works and if it is safe over a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have moderate to severe hidradenitis suppurativa (Hurley stage II or III).
- Your HS diagnosis was confirmed by a biopsy (tissue sample) at our hospital.
- You will receive secukinumab injections along with surgery.
- You have complete medical records and can be followed up for at least one year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether applying secukinumab as a topical cream or as a subcutaneous injection is more effective and safer for treating hidradenitis suppurativa (a skin condition causing painful lumps). It aims to find a better way to manage symptoms in people whose condition has not improved with standard treatments.
This study tests a new medicine given by injection (anti-IL-17A/F antibody) combined with a laser treatment (non-ablative dot laser) for people with mild to moderate hidradenitis suppurativa (also called HS). The goal is to see if the combination is safe and works better than current options, and might help reduce pain and flare-ups.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
Hear when a new Hidradenitis Suppurativa (Acne Inversa) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.